Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

Is Apellis Pharmaceuticals a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 2 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals or view top-rated stocks.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Apellis Pharmaceuticals.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Wednesday, May, 4th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by $0.07. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 607.37% and a negative net margin of 866.81%. During the same quarter last year, the firm earned ($2.32) earnings per share.
View Apellis Pharmaceuticals' earnings history.

What price target have analysts set for APLS?

14 analysts have issued 1-year price targets for Apellis Pharmaceuticals' stock. Their forecasts range from $28.00 to $102.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $69.64 in the next year. This suggests a possible upside of 71.5% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:

• Dr. Cedric Francois M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 50, Pay $969.54k)
• Dr. Pascal Deschatelets Ph.D., Co-Founder & Chief Scientific Officer (Age 52, Pay $609.85k)
• Dr. Federico Grossi M.D., Ph.D., Co-Founder & Chief Medical Officer (Age 48, Pay $578.01k) (LinkedIn Profile)
• Mr. Alec Machiels J.D., MBA, Co-Founder & Director (Age 49, Pay $72.5k) (LinkedIn Profile)
• Mr. Timothy E. Sullivan, CFO & Treasurer (Age 51, Pay $630.17k)
• Mr. Adam J. Townsend, Chief Commercial Officer (Age 45, Pay $602.69k)
• Ms. Nur Nicholson, Chief Technical Operations Officer
• Mr. James G. Chopas CPA, VP, Corp. Controller & Chief Accounting Officer (Age 56)
• Ms. Meredith Kaya, Sr. VP, Investor Relations & Strategic Fin.
• Mr. David O. Watson, Gen. Counsel (Age 49) (LinkedIn Profile)

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

6 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Apellis Pharmaceuticals' key competitors?

Some companies that are related to Apellis Pharmaceuticals include Shiseido (SSDOY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Ono Pharmaceutical (OPHLF), BeiGene (BGNE), Elanco Animal Health (ELAN), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Teva Pharmaceutical Industries (TEVA), Organon & Co. (OGN), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS) and Maravai LifeSciences (MRVI).
View all of APLS's competitors.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.04%), BlackRock Inc. (5.56%), State Street Corp (2.73%), Jennison Associates LLC (2.54%), Victory Capital Management Inc. (1.24%) and Bellevue Group AG (1.03%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals.

Which major investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Victory Capital Management Inc., Candriam Luxembourg S.C.A., SG Americas Securities LLC, Frontier Capital Management Co. LLC, Walleye Capital LLC, Pier Capital LLC, and Integral Health Asset Management LLC. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Alec Machiels, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Nicole D Perry, and Pascal Deschatelets.
View insider buying and selling activity for Apellis Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Apellis Pharmaceuticals stock?

APLS stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Vanguard Group Inc., Bellevue Group AG, Assenagon Asset Management S.A., Maven Securities LTD, Artal Group S.A., State Street Corp, and Prudential Financial Inc..
View insider buying and selling activity for Apellis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $40.61.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals has a market capitalization of $4.33 billion and generates $66.56 million in revenue each year. The company earns $-746.35 million in net income (profit) each year or ($8.03) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals employs 476 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at (617) 977-5700 or via email at [email protected].